Enhancing the Immunogenicity of RBD Protein Variants through Amino Acid E484 Mutation in SARS-CoV-2.

Abstract excerpt

In the context of the COVID-19 pandemic, conducting antibody testing and vaccination is critical. In particular, the continued evolution of SARS-CoV-2 raises concerns about the effectiveness of vaccines currently in use and the activity of neutralizing antibodies. Here, we used the Escherichia coli expression system to obtain nine different SARS-CoV-2 RBD protein variants, including six single-point mutants, one...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Neutralizing
• Share to Antibodies, Viral
• Share to Mutant Proteins